Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Danish drugmaker Novo Nordisk said on Tuesday Japan's health regulator had approved its new combination insulin, that it plans to market as Ryzodeg, for the treatment of diabetes.
Ryzodeg is a combination of Novo's new ultra long-acting insulin degludec, or Tresiba, which Japan became the first country to approve in September, and its rapid-acting insulin Novorapid.
http://uk.reuters.com/article/2012/12/25/us-novonordisk-idUKBRE8BO02F20121225
Ryzodeg is a combination of Novo's new ultra long-acting insulin degludec, or Tresiba, which Japan became the first country to approve in September, and its rapid-acting insulin Novorapid.
http://uk.reuters.com/article/2012/12/25/us-novonordisk-idUKBRE8BO02F20121225